Bionomics share price

Bionomics PTSD drug, BNC210 phase 2 trial, Bionomics share price, PTSD treatment, Bionomics biopharmaceutical company, BNC210 mechanism of action, PTSD clinical trial,

Bionomicsā€™ PTSD drug shows positive results in phase 2 trial, boosting its share price

Anika Sharma

Bionomics is making a remarkable resurgence following a significant setback caused by the failure of an anxiety trial, with investors ...